CLINICAL TRIALS

Bladder Cancer Clinical Trials in Washington DC

10+ recruiting Bladder Cancer trials in Washington DC, simplified into plain English.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

RECRUITINGPhase 2

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer. The primary goal of this trial is to assess the pathologic complete

NCT05312671 · Washington D.C.
RECRUITINGPhase 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will

NCT07218380 · Huntsville
RECRUITINGPhase 2

Renal Retention in High Grade Upper Tract Urothelial Cancer

This trial will evaluate the use of combination pembrolizumab and enfortumab vedotin for patients with high grade non-metastatic (cN0/NxMx, no measurable regional lymph nodes, no metastases) upper tract urothelial cancer

NCT05656235 · Washington D.C.
RECRUITING

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

The purpose of this study is to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG). Patients with Non-Muscle Invasive Bladder Cancer rec

NCT05672615 · Washington D.C.
RECRUITINGPhase 3

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this tri

NCT06545955 · Tucson
RECRUITINGNA

Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy

The purpose of this clinical trial is to determine if prostate-capsule-sparing cystectomy improves functional outcomes without comprising oncologic outcomes in male patients receiving a radical cystectomy. Patients will

NCT05792722 · Washington D.C.
ACTIVE NOT RECRUITINGPhase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it fir

NCT02465060 · Birmingham
RECRUITING

Blue Light Cystoscopy With Cysview® Registry

Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

NCT02660645 · Birmingham
RECRUITINGPhase 1

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a

NCT04752722 · Birmingham
ACTIVE NOT RECRUITINGPhase 3

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcita

NCT03682068 · Birmingham

RECOMMENDED RESOURCES FOR BLADDER CANCER

🛡️

GoHealth

Medicare Specialist

Compare Medicare Advantage and Supplement plans with a licensed advisor. Many patients with chronic conditions qualify for $0-premium plans with extra benefits.

Check Your Coverage →
💼

eHealth Insurance

Licensed Agents

Shop ACA health plans from top insurers. Licensed agents help you find coverage that works with clinical trial participation — at no cost to you.

Compare Plans Free →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Bladder Cancer clinical trials in Washington DC?

Yes. Clinicals AI lists 10+ recruiting Bladder Cancer trials in Washington DC sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Bladder Cancer trial in Washington DC?

Eligibility varies by study. Most trials require a confirmed Bladder Cancer diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Bladder Cancer clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.